Two Experts Take on Biotech: TheStockAdvisors.com Features John McCamant and Michael Shulman :: Business Articles and Info

Sunday, 06th July 2008

home about authors news books xml feed sitemap privacy contact us

There are 2 users online

make home page

Books and Reading
Business Education
Business Industry
Business Services and Assistants
Business Technology
Corporate Companies
Current Events
E-Commerce and Internet
Economics
Employment and Opportunities
Finances
International Business
Investing
Management Editorials
Partnerships and Affiliate Programs
Promotion and Marketing
Seminars and Salesmanship
Small/Home Business
Statistics
Tax Related
The Stock Market
Tips and Strategies
Tools for Business

Our Newsletter

Other Resources

For other sources of business news, tips, and information, visit our resources page

Submit an Article

Would you like to have your article posted?

More info on business issues

Two Experts Take on Biotech: TheStockAdvisors.com Features John McCamant and Michael Shulman
Added: 06/26/2006 Type: Tip Viewed: 377 time(s) [ Not Rated Yet ]

How would you rate this article: Bad Good Go »

Printer Friendly Version

Two Experts Take on Biotech: TheStockAdvisors.com Features John McCamant and Michael Shulman

TheStockAdvisors.com (http://www.thestockadvisors.com), an interactive guide to financial newsletters announced today that it has provided readers with comments from two leading stock advisory groups. John McCamant and Michael Shulman comment on their outlook for two biotech companies BioCryst (BCRX: NASDAQ) and Genetech (DNA: NYSE).

When it comes to biotech stocks, few advisors have the long-standing expertise enjoyed by John McCamant. His success in finding opportunities among biotech stocks for his Medical Technology Stock Letter is based not just on analytic skills, but an in-depth understanding of the research underlying the sector, as well as direct contact and experience with researchers, analysts, venture capitalists, and executives in the sector.

Go direct to the full article: http://www.thestockadvisors.com/content/view/149/9/

"What is the most promising new technological or scientific approach as a long-term investment? The answer is personalized medicine -- including several trends currently in scientific development. Personalized medicine -- called ‘ME’ medicine -- is a very broad category of development categories and companies. The stocks in this emerging area are not yet in favor among institutional investors. The Street does not yet believe in most personalized treatments and this creates a great opportunity for us. Here, the editor of ChangeWave Biotech Investor looks at “the next great drug company.”

Go direct to the full article: http://www.thestockadvisors.com/content/view/55/9/

All readers on TheStockAdvisors.com receive free access to professional commentary and research from the top investing newsletters and their advisors.

TheStockAdvisors.com also offers a bi-weekly email which offers the best picks from the week’s posts. Subscribe for free at the sign-up box on our site: http://www.thestockadvisors.com

About TheStockAdvisors.com:

TheStockAdvisors.com is the first ever interactive site for individual investors and financial newsletter advisors. Steven Halpern, the editor of TheStockAdvisors.com, with his 24 years of experience as a financial newsletter editor, has set a goal to help investors learn from the most qualified, unbiased, and independent financial newsletter advisors.

We encourage users to actively participate in interactive forums, share feedback, and support our participating advisors. To subscribe to any of our featured newsletters, all names are conveniently linked to their respective websites.

Article Pages: 1

Article Comments

Add Comment |

View All (0)

There are currently no comments for this article.

Advanced Search


More Resources
Become a Day Trader Early Warning Services ecommerce shopping cart Find the Perfect Job Affiliate With Us